trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['enhertu', '$dsnky', '$azn']
enhertu hits with pan approach, but will regulators agree to a tumour agnostic label? my take on the destiny-pantumour02 data, just released at #asco23 $azn $dsnky 
Pharma and biotech reporter, found a home at Evaluate Vantage.